According to the latest published information, Graviola has been researched in laboratory tests since the 1970s, where it's been shown to: * Effectively target and kill malignant cells in 12 different types of cancer, including Colon, Breast, Prostrate, Lung and Pancreatic Cancer. * Be 10,000 times stronger in killing colon cancer cells than Adriamycin (a commonly used chemotherapeutic drug). * Selectively hunt down and kill cancer cells without harming healthy cells, unlike chemotherapy. In an 1976 plant screening program by the National Cancer Institute, the leaves and stem of Graviola showed active cytotoxicity against cancer cells and researchers have been following up on this research ever since. Much of the research on Graviola focuses on a novel set of phytochemicals called annonaceous acetogenins. The potent antitumor, pesticidal and/or insect antifeedant properties of these annonaceous acetogenins have been reported and patented. Graviola produces these natural compounds in leaf, bark and twig tissues, and they have be documented to possess both highly anti-tumor and pesticidal properties. In the June issue of Cancer Letters, the Purdue researchers reported that the annona acetogenin, bullatacin, preferentially killed multi-drug resistant cancer cells because it blocked production of adenosine triphosphate, ATP -- the chief energy-carrying compound in the body. "A multi-drug resistant cell requires a tremendous amount of energy to run the pump and extrude things out of the cell," McLaughlin says. "By inhibiting ATP production, we're essentially pulling the plug on its energy source." But what about the effect on ATP in normal cells? "Normal cells and standard cancer cells may be able to minimize the effect of this compound because they don't require vast amounts of energy needed by the pump-running cells," the Purdue researcher says. "The resistant cell is using its extra energy for this pump as well as to grow, so it is really taxed for energy. When we mess with the energy supply, it kills the cell."